NCT02608177View on ClinicalTrials.gov

Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management

NACompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2018

Conditions
Chronic Kidney DiseasesType 2 Diabetes
Interventions
DRUG

Linagliptin

Receives 4 weeks of study drug linagliptin

DRUG

Glipizide

Receives 4 weeks of study drug glipizide

Trial Locations (1)

Unknown

University of Washington, Seattle

Sponsors

Collaborators (2)

Medtronic
Abbott
All Listed Sponsors
collaborator

American Diabetes Association

OTHER

collaborator

Medtronic

INDUSTRY

collaborator

Abbott

INDUSTRY

lead

University of Washington

OTHER

NCT02608177 - Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management | Biotech Hunter | Biotech Hunter